Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991172 | 0.98 | OPRD1 (0.54) | OPRD1OPRM1OPRK1ENPEPCASP1 | |
| SCHEMBL6516934 | 0.94 | BACE1 (0.57) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL30420544 | 0.92 | OPRD1 (0.54) | OPRD1OPRM1OPRK1CASP1BACE1 | |
| SCHEMBL29600830 | 0.92 | OPRD1 (0.54) | OPRD1OPRM1OPRK1CASP1BACE1 | |
| SCHEMBL29605141 | 0.90 | BACE1 (0.60) | OPRD1OPRM1OPRK1ENPEPBACE1 | |
| SCHEMBL30436583 | 0.90 | BACE1 (0.60) | OPRD1OPRM1OPRK1ENPEPBACE1 | |
| SCHEMBL30086863 | 0.89 | OPRD1 (0.53) | OPRD1OPRM1OPRK1NPY1RNPY2R | |
| SCHEMBL29822851 | 0.89 | OPRD1 (0.64) | OPRD1OPRM1OPRK1NPY1RNPY2R | |
| SCHEMBL30799816 | 0.89 | OPRD1 (0.47) | OPRD1OPRM1OPRK1ENPEPBACE1 | |
| SCHEMBL30799740 | 0.88 | LTA4H (0.58) | OPRD1OPRM1OPRK1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | OPRD1 4412/4885OPRM1 4382/4885OPRK1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.